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Objective: This study identifies specific clinical and immunologic factors 
in lung transplant recipients that influence the subsequent development 
of chronic allograft dysfunction. Methods: The study group consisted of 
132 consecutive patients who received lung allografts (76 single, 25 
bilateral single, and 31 heart-lung) and survived at least 90 days. One 
hundred twenty-one patients were used in the analysis that modeled 
time to development of histologic obliterative bronchiolitis or bronchi- 
olitis obliterans yndrome. Results: Variables noted to have an effect on 
the time to development of bronchiolitis obliterans yndrome included 
cytomegalovirus pneumonitis (RR = 3.2,p = 0.001), late acute rejection 
(RR = 1.3,p = 0.02), human leukocyte antigen mismatches at the A loci 
(RR = 1.8, p = 0.02), total human leukocyte antigen mismatches (RR = 
1.4, p = 0.04), and absence of donor antigen-specific hyporeactivity 
(52% vs 100% survival free from bronchiolitis obliterans yndrome at 2 
years; p = 0.005). Cytomegalovirus pneumonitis had a significant effect 
on time to obliterative bronchiolitis (RR = 3.6, p = 0.0005), as did donor 
antigen-specific hyporeactivity (52% vs 100% survival free from oblit- 
erative bronchiolitis at 2 years; p = 0.01). In multivariate analysis, 
cytomegalovirus pneumonitis (RR = 3.2, p = 0.02), human leukocyte 
antigen mismatches at the A loci (RR = 2.4, p = 0.006), and late acute 
rejection (RR = 1.3, p = 0.02) were identified as predictors of 
bronchiolitis obliterans syndrome. Cytomegalovirus pneumonitis was 
associated with time to development of histologic obliterative bronchi- 
olitis (RR = 2.3, p = 0.02). Conclusions: Several risk factors were 
associated with the development of chronic allograft dysfunction, which, 
in turn, had a significant impact on long-term survival. Early identifi- 
cation of lung allograft recipients with risk factors for the development 
of bronchiolitis obliterans yndrome may allow modification in immu- 
nosuppression and antiviral therapy to potentially decrease the preva- 
lence of this disorder. (J Thorac Cardiovasc Surg 1997;114:195-202) 
C hronic lung dysfunction has emerged as the most significant long-term complication after lung 
transplantation. 1'2 Chronic lung dysfunction was 
defined by criteria established for patients with 
bronchiolitis obliterans syndrome (BOS). 3 BOS is 
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presumed to be due to chronic allograft rejection 
and is characterized clinically by a progressive de- 
cline in pulmonary function with the presence or 
absence of pathologic evidence of obliterative bron- 
chiolitis (OB). OB is frequently unresponsive to 
medical therapy, with retransplantation being the 
only therapeutic option for many patients. An im- 
proved understanding of the pathogenesis of OB is 
essential to design rational approaches for its pre- 
vention and treatment. The mechanisms and predis- 
posing factors leading to the development of OB are 
presently not fully clear. 4 To identify possible risk 
factors for chronic allograft dysfunction, we used 
univariate and multivariate analyses to compare the 
demographic, immunologic, and clinical character- 
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istics of patients after lung or heart- lung transplan- 
tation who have BOS and those who have stable 
graft function. 
Methods 
Patient population. A retrospective r view of 149 con- 
secutive patients undergoing pulmonary transplantation 
from May 1986 to January 1995 was conducted to deter- 
mine the survival rate free from the development of 
chronic allograft dysfunction in the posttransplantation 
period. One hundred thirty-two patients met the study 
criteria, surviving at least 3 months after transplantation: 
3l received heart-lung transplants, 25 bilateral sequential 
lung transplants, and 76 single lung transplants. Complete 
data were available to model time to OB or BOS status on 
88 of the 132 patients; in 121 patients all data were 
available except HLA matching. Operative techniques 
used have previously been reported. 5 
Criteria for diagnosis of BOS and OB. The staging of 
BOS was based on criteria defined for pulmonary function 
data and histopathology from transbronchial lung biopsy 
results obtained in the posttransplantation periodfl For 
the purpose of this analysis, two end points were defined. 
OB was defined as histologically proved OB. 6 BOS was 
defined as a BOS grade of 2 or 3. 
Immnnosuppression. Standard induction triple immu- 
nosuppression therapy was instituted in the immediate 
preoperative period. The drugs consisted of cyclosporine 
(3 to 6 mg/kg; INN: ciclosporin) and azathioprine (2.5 
mg/kg), as well as perioperative methylprednisolone (500 
mg) immediately before graft perfusion followed by 125 
mg every 8 hours for three doses thereafter. Before 1990, 
oral steroids were withheld for 14 days after transplanta- 
tion in lung allograft recipients after the perioperative 
administration of methylprednisolone. An oral steroid 
taper was then initiated. From 1990 to the present ime 
this taper was started immediately after perioperative 
coverage consisting of prednisone at 0.5 mg/kg per day 
and tapering to 0.1 mg/kg per day by 3 to 6 months. 
Infectious disease prophylaxis. Prophylactic antibacte- 
rial agents were given in the perioperative period. All 
patients received trimethoprim/sulfamethoxazole twice 
weekly orally or pentamidine by aerosol inhalation 
monthly for Pneumocystis carinii prophylaxis. In the pres- 
ence of donor or recipient CMV seropositivity, the fol- 
lowing evolution in prophylaxis has occurred. CMV pro- 
phylaxis was first initiated in 1989, consisting of acyclovir 
(INN: aciclovir) at 800 mg four times a day. Between 
December 1991 and December 1992, patients received 
ganciclovir 5 mg/kg twice daily for 14 days, followed by 5 
mg/kg per day for 8 weeks. From January 1993 all patients 
received ganciclovir 5 mg/kg twice daily for 14 days 
followed by 5 mg/kg per day for 8 weeks or 5 mg/kg three 
times a week for 8 weeks. 
Management of acute rejection. Acute rejection epi- 
sodes were managed with intravenous bolus doses of 
methylprednisolone (500 to 1000 rag) for 3 days followed 
by an oral steroid taper. Patients with steroid-resistant 
rejection were treated with antithymocyte globulin for 7 to 
10 days or with methotrexate. 
CMV pneumonitis. The diagnosis of CMV was divided 
into two categories (1) CMV pneumonitis--a new pulmo- 
nary infiltrate, fever, cough, dyspnea, and new CMV 
culture positivity or cytologic evidence of typical CMV 
inclusions on bronchoalveolar lavage (BAL) or his- 
topathologic study and (2) asymptomatic CMV infec- 
tion-isolation of CMV from BAL in the absence of 
clinical signs or symptoms. Only CMV disease before the 
development of BOS was used in this analysis. 
Donor antigen-specific hyporeaetivity (DASH) test. 
Peripheral blood samples were obtained from 29 lung 
transplant recipients I year after transplantation. A mixed 
lymphocytotoxicity assay was used to identify donor anti- 
gen-specific hyporeactivity (DASH) with homozygous 
typing cells as stimulator cells and recipient cells as 
responder cells, as previously described. 7 Hyporeactivity 
was defined as a decreased response to stimulation by 
specific typing cells that define donor antigens, whereby 
response to homozygous typing cells defining third-party 
antigens remained unchanged. 
Primed lymphocyte test (PLT). The primed lympho- 
cyte test (PLT) is a method used to detect he lymphocyte- 
defined determinants associated with the MHC antigens. 4 
The principle of the PLT technique is to generate re- 
sponder cells against disparities expressed by the stimula- 
tor cell by incubating the cells together for 10 days. These 
primed cells, presumably memory cells, respond in an 
accelerated manner, that is, secondary response, when 
restimulated by cells from the original stimulator or other 
cells that share stimulatory determinants with the sensi- 
tizing stimulating cell. 
Statistical analysis. The impact of various predictive 
factors on time to development of BOS or OB was 
assessed by means of proportional hazards regression)' 9 
Proportional hazards regression was chosen for assessing 
predictors of time to BOS and OB because it does not 
require the specification of a probability distribution for 
the underlying survival times. The proportional hazards 
regression model specifies that the hazard for an individ- 
ual person is a product of an underlying hazard function 
multiplied by a factor depending on the set of covariates 
for that patient. It also allows for the incorporation of 
covariates that may change value over the period of 
observation. 10
Proportional hazards regression generates risk ratios 
(RR) for each covariate in the model. These RRs reflect 
the increase (RR > 1) or decrease (RR < 1) in probability 
of BOS for each one-unit increase in the covariate. In the 
multivariate model, the RRs for a specific covariate are 
adjusted for the effects of the other covariates in the 
model. Analyses were performed by means of SAS and 
SPSS (SAS Institute, Inc., Cary, N.C.; SPSS, Inc., Chicago, 
hi.). 
Four time-dependent covariates were considered be- 
fore diagnosis of BOS or OB: CMV pneumonitis, counts 
of acute rejection, counts of late acute rejection more than 
3 months after transplantation, and a positive PLT result. 
At each specific failure time, status of CMV pneumonitis 
or PLT was reassigned from negative to positive if a status 
change had occurred since the last failure time. For 
cumulative counts of rejection, the status was incremented 
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by as many episodes of rejection as had occurred since the 
last failure time. 
Even though patients were included in this assessment 
only if they had survived 90 days or longer, it was decided 
to use the date of transplantation as time zero, recogniz- 
ing that survival and survival free from BOS or OB would 
be 100% at 90 days. Because no events occurred in this 
period, the fact that the starting point was transplantation 
rather than 90 days had no real effect on the model. This 
was done for two reasons. First, transplantation is a 
natural starting point for follow-up. Second, beginning 
follow-up at 90 days would require several possible risk 
factors to be captured as two variables, one fixed and one 
time-dependent, making interpretation even more com- 
plex. For example, CMV pneumonitis developed before 
90 days in some patients and after 90 days in others. Thus 
two variables for CMV pneumonitis would have been 
needed for each subject, one fixed that captured CMV 
status before 90 days and one time-dependent that cap- 
tured CMV status after 90 days. 
Two types of modeling were done. One set of models 
was based on what clinicians believed were predictive 
factors for development ofBOS or OB based on practice. 
Another set of models was based on a stepwise regression 
analysis, with the use of the variables pecified in the 
clinical model. Variables whose status changed over time 
after transplantation (CMV pneumonitis, PLT, cumula- 
tive episodes of acute rejection, and late acute rejection) 
were handled as time-dependent covariates. PLT and 
DASH were not included in the multivariate analysis 
because of the small number of subjects with these values. 
The impact of chronic lung dysfunction on survival was 
also assessed by means of a proportional hazards regres- 
sion, with development of BOS or OB as a time-depen- 
dent covariate. This was done to confirm, with our specific 
patient group, the widely known association between 
development of BOS or OB and increased mortality. To 
illustrate the effect of BOS on survival, we generated three 
Kaplan-Meier curves al on subgroups of patients defined 
by specific time points: (1) those who survived beyond 1 
year and in whom BOS was diagnosed before I year versus 
those who had survived longer than 1 year and in whom 
BOS had not been diagnosed by 1 year; (2) those who 
survived beyond 2 years and in whom BOS was diagnosed 
before 2 years versus those who had survived longer than 
2 years and in whom BOS had not been diagnosed by 2 
years; (3) those who survived beyond 3 years and in whom 
BOS was diagnosed before 3 years versus those who had 
survived longer than 3 years and in whom BOS had not 
been diagnosed by 3 years. 
Results 
Patient population and survival. The demo- 
graphic, clinical, and survival characteristics for the 
121 patients in this study are summarized in Table I 
and Fig. 1. Patients with BOS demonstrated a 
reduction in survival (RR = 7.2, p = 0.0001). Fig. 1 
illustrates urvival for patients with BOS who have 
reached certain time points versus those patients in 
whom BOS has not developed by these time points. 
Table I. Demographic haracteristics of lung 
allograft recipients (n = 121) 
Age (yr) 42 _+ 13 
Sex 
Male 50 
Female 71 
Primary disease 
Primary pulmonary hypertension 24 
Eisenmenger's syndrome 12 
al-Antitrypsin deficiency 30 
Chronic obstructive pulmonary disease 29 
Idiopathic pulmonary fibrosis 9 
Others 17 
Transplant type 
Heart-lung 28 
Bilateral single lung 22 
Single lung 72 
Ischemic time (min) 252 _+ 102 
Survival was also significantly different for patients 
with OB compared with those without OB (RR = 
5.3,p = 0.0001). 
Initial analysis. Recipient primary disease, type 
of transplant, age, ischemic time, CMV pneumoni- 
tis, PLT, total cumulative counts of acute rejection, 
counts of rejection episodes before 90 days, cumu- 
lative counts of late rejection after 90 days, and 
treatment regimens were evaluated as risk factors 
for the development of chronic lung dysfunction. 
Results are summarized in Tables II and III. 
Age was dichotomized into two major groups 
(>-50 years and <50 years) on the basis of an 
association with OB observed in a previous tudy. 12 
With this larger patient sample, this association was 
no longer significant. No significant difference be- 
tween groups was noted in primary disease, donor 
organ ischemic time, steroid treatment, sex, time on 
the waiting list before transplantation, or follow-up. 
CMV pneumonitis. The development of symp- 
tomatic CMV pulmonary infection before diagnosis 
of BOS was a significant risk factor for development 
of BOS (RR = 3.2, p = 0.0001) and for the 
development of OB (RR = 3.6, p = 0.0005). The 
effect of the three CMV prophylaxis protocols on 
time to development of CMV pneumonitis was 
assessed as a possible confounding factor. There was 
no significant effect of the two later protocols com- 
pared with the first protocol on time to CMV 
pneumonitis (RR = 1.1, p = 0.95; and RR = 1.0, 
p = 0.99, respectively). Asymptomatic CMV had no 
effect on time to BOS or OB. 
Acute rejection. Episodes of acute rejection were 
looked at in two phases. Number of episodes of 
1 9 8 Kroshus et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
August 1997 
1 
0.8 
0.6 
o.4 
0.2 
o 
A 
proportion surviving 
1 
~never diagnosed with Bog 
--Diagnosed with BOS by 12 months 
12 24 36 48 60 72 84 96 108 120 
survival in months 
B 
0.8 
0.6  
0.4 
0.2 
0 
proportion surviving 
12 24 36 
mNever  diagnosed with BOS 
- -D iagnosed with BOS by 24 months 
48 60 72 84 96 108 120 
survival in months 
1 
0.8 
0.6 
0.4 
0.2 
0 
proportion surviving 
I 
--Never diagnosed with BOS 
--Diagnosed with BOS by 36 months 
0 12 24 36 48 60 72 84 96 108 120 
C survival in months 
Fig. 1. A, Cumulative survival beyond 12 months for 
patients in whom BOS was diagnosed by 12 months 
compared with those patients in whom BOS was not 
diagnosed by 12 months. B, Cumulative survival beyond 
24 months for patients in whom BOS was diagnosed by 24 
months compared with those patients in whom BOS was 
not diagnosed by 24 months. C, Cumulative survival 
beyond 36 months for patients in whom BOS was diag- 
nosed by 36 months compared with those patients in 
whom BOS was not diagnosed by 36 months. 
acute rejection before 90 days was not significantly 
associated with time to development of BOS (RR = 
1.2, p = 0.12) or OB (RR = 1.0, p = 0.83). 
Cumulative episodes of late acute rejection were 
significantly associated with time to development of
BOS (RR = 1.3, p = 0.02). In contrast, the devel- 
opment of OB was not associated with cumulative 
episodes of late acute rejection (RR = 0.8, p = 
0.55). The effect on time to BOS or OB of total 
cumulative counts of acute rejection was also as- 
sessed to see whether there was a stronger effect. 
There was a significant, but not stronger, impact on 
time to BOS (RR = 1.2,p -- 0.009), but not on time 
to OB (RR = 0.9,p = 0.31). 
HLA mismatches. Mismatches at the A loci, as 
well as the total number of HLA mismatches, were 
found to be significant risk factors for the develop- 
ment of BOS. Mismatches at the B loci or the DR 
loci, when considered individually, were not found 
to have an effect on the development of BOS. 
Number of HLA mismatches was not associated 
with time to OB. 
DASH test. In an experimental study, the DASH 
test was performed in 29 patients. No recipients with 
DASH have had a diagnosi  of chronic lung dysfunc- 
tion (2-year survival free from BOS, 100% vs 52%; 
p = 0.005) or of histologically proved OB (2-year 
survival free from OB, 100% vs 52%; p = 0.01). 
Multivariate proportional hazards regression 
model based on clinical experience. A model was 
evaluated that included all variables thought o have 
value in predicting development of BOS or OB 
based on clinical experience, regardless of statistical 
association. That model included age older than 50 
years, HLA mismatches at the A loci, primary 
pulmonary hypertension, steroid regimen, rejection 
episodes before 90 days, cumulative episodes of 
acute rejection, and CMV pneumonitis. Late acute 
rejection, CMV pneumonitis, and HLA mismatches 
at the A loci were associated with the development 
of BOS (n = 88; Table IV). Repeated analysis 
without he HLA data (n = 121) had similar results. 
Only CMV pneumonitis was associated with the 
development of OB. 
Multivariate proportional hazards regression 
models based on statistical criteria. Using the vari- 
ables specified in the clinical model, CMV pneumo- 
nitis, HLA mismatches at the A loci, and cumulative 
episodes of late acute rejection were significantly 
associated with the development of BOS (n = 88; 
Table V). The only variable that was a significant 
predictor of time to OB was CMV pneumonitis 
(RR = 2.3, p = 0.02). Resulting models on the 121 
patients excluding the HLA data had the same 
significant associations with similar relative risks. 
Discussion 
The major factor affecting the long-term survival 
after lung transplantation is chronic allograft dys- 
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Table II. Assessment of individual fixed covariates for two end points by proportional hazards regression." 
Biopsy-proved OB and BOS 
BOS >- 2 OB 
RR 95% CI p Value RR 95% CI p Value 
Diagnostic group 
cq-AT + COPD (ref grp) 
PPH + Eisenmenger's 0.96 0.48-1.9 0.96 1.4 0.6-3.0 0.44 
Other 1.1 0.49-2.4 0.92 0.9 0.3-2.4 0.78 
PPH only 1.2 0.6-2.3 0.67 1.6 0.7-3.5 0.23 
Transplant type 
Single lung (ref grp) 
Bilateral single lung 0.76 0.31-1.9 0.55 1.1 0.4-3.1 0.81 
Heart-lung 0.82 0.40-1.7 0.58 1.2 0.5-2.6 0.70 
Age 
<50 yr (ref grp) 
>50 yr 0.96 0.5-1.8 0.89 0.54 0.2-1.3 
Sex: female 1.0 0.6-1.8 0.91 1.3 0.6-2.5 0.51 
Ischemic time 1.0 0.9-1.1 0.84 1.0 0.9-1.0 0.40 
Steroid treatment 0.76 0.4-1.5 0.42 0.7 0.3-1.5 0.34 
(before 1991--ref grp) 
HLA mismatches 
A loci 1.8 1.0-3.2 0.04 1.3 0.7-2.5 0.43 
B loci 1.5 0.7-3.1 0.26 1.1 0.5-2.5 0.75 
DR loci 1.2 0.7-2.1 0.44 1.1 0.6-2.1 0.71 
Total mismatches 1.4 1.0-1.9 0.04 1.1 0.8-1.6 0.47 
Days on waiting list 1.0 0.9-1.0 0.84 1.0 0.9-1.0 0.19 
Rejection episodes 1.2 0.9-1.6 0.11 1.0 0.7-1.4 0.83 
(first 90 days) 
al-AT, c~l-Antitrypsin deficiency; CI, confidence interval; COPD, chronic obstructive pulmonary disease; PPIt, primary pulmonary hypertension; ref grp, 
reference group. 
Table III. Assessment of time-dependent covariates for two end points by proportional hazards regression." 
Biopsy-proved OB and BOS 
BOS >- 2 OB 
RR 95% CI p Value RR 95% CI p Value 
CMV pneumonitis 3.2 1.8-5.8 
Total cumulative pisodes 1.2 1.0-1.4 
of acute rejection 
Cumulative pisodes of 1.3 1.0-1.5 
late acute rejection 
PLT class II 1.3 0.6-2.9 
0.0001 3.6 1.8-7.3 0.0005 
0.009 1.1 0.9-1.3 0.31 
0.02 0.9 0.8-1.2 0.55 
0.49 1.7 0.7-4.4 0.23 
function, thought to be synonymous with chronic 
rejection. This syndrome is a major cause of late 
morbidity and mortality for lung allograft recipients. 
The term BOS has been used to describe such 
dysfunction, with a staging system based on forced 
expiratory volume in 1 second, with or without 
pathologic evidence of OB. 3 This system was de- 
signed to allow comparison of results between insti- 
tutions owing to the low sensitivity of transbronchial 
biopsies in detecting OB 13 and a high incidence of 
OB not detected clinically but found at autopsy in 
patients with chronic lung dysfunction ot attributed 
to other causes. 2 
OB is a progressive obstructive airway disease 
identified histologically by the presence of small 
airway inflammation and fibrosis of the lamina 
propria and lumen and characterized clinically by 
rapidly progressive airflow obstruction. OB was first 
reported after heart-lung transplantation in 1985.14 
OB is a major cause of death and disability in 
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Table IV. Multivariate proportional hazards model 
predicting BOS and OB based on clinical variables 
(n = 88) 
RR 95% CI p Value 
BOS ->2 
Acute rejection (<90 days) 1.2 0.8-1.6 0.40 
Cumulative pisodes of acute 1.2 1.0-1.5 0.04 
rejection 
CMV pneumonitis 3.4 1.7-6.8 0.0005 
Age >50 yr 0.9 0.4-2.0 0.83 
HLA mismatches at A loci 2.1 1.1-4.2 0.03 
Primary pulmonary hypertension 1.7 0.7-4.0 0.20 
Steroid regimen after 1990 0.9 0.4-1.9 0.70 
OB 
Acute rejection (<90 days) 1.1 0.7-1.7 0.63 
Cumulative pisodes of acute 0.9 0.7-1.1 0.30 
rejection 
CMV pneumonitis 2.4 1.1-5.5 0.04 
Age >50 yr 0.5 0.2-1.5 0.24 
HLA mismatches atA loci 1.2 0.6-2.3 0.60 
Primary pulmonary hypertension 1.3 0.5-3.4 0.64 
Steroid regimen after 1990 0.6 0.2-1.7 0.34 
long-term survivors of lung transplantation, occur- 
ring in up to 50% of patients urviving the first year 
after transplantation, is Augmentation of immuno- 
suppression has been advocated and appears to 
ameliorate or stabilize the disease process in some 
patients.16, 17 Despite this, OB often progresses re- 
lentlessly, leading to death. Identifying risk factors 
for OB is an important goal so that patients in whom 
the risk is high can receive close surveillance and 
early treatment. Risk factors identified by this anal- 
ysis included CMV pneumonitis, acute rejection 
after 90 days, negative DASH test results, number of 
HLA mismatches at the A loci, and total number of 
HLA mismatches. 
The immunopathogenic mechanisms leading to 
the development of OB are incompletely under- 
stood. An experimental large animal model of OB 
demonstrated increased lymphocyte counts with 
CD8+ cells predominating on BAL and increased 
expression of MHC class II antigens on the bron- 
chiolar epithelium after the development of OB) s 
Studies performed at our institution have identified 
BAL-derived lymphocytes demonstrating PLT reac- 
tivity that correlated with MHC antigen expression 
with stable or minimally progressive versus rapidly 
progressive OB. 4 These studies demonstrated the 
role of augmented immunosuppressive therapy in 
halting or slowing this disease process in selected 
patients with PLT reactivity against class II antigens; 
by contrast, PLT reactivity against class I antigens 
Table V. Multivariate proportional hazards model 
predicting BOS and OB based on stepwise regression 
RR 95% CI p Value 
BOS -> 2 
Cumulative pisodes of 1.3 1.0-1.6 0.02 
acute rejection 
CMV pneumonitis 3.2 1.7-6.2 0.0006 
HLA mismatches at A loci 2.4 1.3-4.6 0.006 
OB 
CMV pneumonitis 2.2 1.1-4.3 0.02 
resulted in progressive OB with all patients dying 
within 6 months of diagnosis. These results suggest 
that distinct immune modulation mechanisms are 
responsible for the subsequent development of OB. 
A decline in survival for patients with BOS was 
predominantly noted to occur 12 to 24 months after 
transplantation, with stabilization of long-term sur- 
vival for those patients surviving beyond 36 to 48 
months. Similar findings were noted in patients with 
or without histologic OB. These findings suggest the 
existence of two pathologic variants of chronic allo- 
graft dysfunction: one that is rapidly progressive and 
associated with death within 24 to 36 months and 
one that is chronically stable and associated with a 
better long-term survival. 
Infections, including those caused by CMV, Pneu- 
mocystis carinii, and Ebstein-Barr virus, have all 
been implicated in the pathogenesis of OB) 9 In this 
study, we found no difference between patients with 
and without chronic lung dysfunction with regard to 
isolation of CMV from BAL fluid obtained from 
symptom-free patients in stable condition. However, 
the development of CMV pneumonitis was signifi- 
cantly associated with chronic lung dysfunction. 
Duncan and associates 2° have also shown that the 
prevalence of chronic rejection was highest among 
patients with CMV-positive results and with biopsy 
or cytology proved pneumonitis. In contrast, Cooper 
and colleagues I reported that posttransplantation 
CMV infections did not influence the subsequent 
development of OB. The reasons for this discrep- 
ancy are not clear. On the basis of our results, 
theoretical approaches would include CMV match- 
ing between donor and recipient, as well as admin- 
istration of prophylactic anti-CMV therapy in lung 
allograft recipients. However, we do not routinely 
perform CMV matching between donor and recipi- 
ent, because this would cause further constraint on 
the availability of donor lungs. Prophylactic anti- 
CMV treatment is now practiced by most lung 
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transplant centers because of favorable results in 
patients undergoing lung, 21 heart, 22 and bone mar- 
row 23 transplantation. Further studies will need to 
be carried out to determine the optimal drug regi- 
men and dosing schedule. 
Acute rejection is a common occurrence in lung 
allograft recipients. In this study we did find a 
correlation between the cumulative count of rejec- 
tion episodes and the subsequent development of 
chronic lung dysfunction. Experimental lung trans- 
plant models have shown the influence of acute 
rejection on the subsequent development of chronic 
rejection.iS, 24 Clinical studies have also implicated 
acute rejection as a significant risk factor for OB. 25 
The intensity and the persistence of early acute 
rejection have been correlated with the develop- 
ment of OB, 26' 27 prompting early detection and 
treatment of acute rejection followed by increased 
maintenance immunosuppression t  achieve normal 
biopsy results. 28 
The concept hat increased immune activation is 
responsible for OB is based on the reactivity of 
specific cells in the lung allograft against donor 
antigens. BAL-derived cells exhibit donor antigen- 
specific alloreactivity in OB when tested in PLT and 
cell-mediated lympholysis assays, a9 Studies at the 
University of Pittsburgh have shown a correlation 
between a positive PLT of BAL cells from patients 
with a negative biopsy and the development of OB 
on a subsequent biopsy. 3°' 31 Studies from the Uni- 
versity of Minnesota have focused on the other end 
of the spectrum of donor-specific reactivity to fur- 
ther add evidence to the immunologic basis of 
chronic allograft rejection] Specifically, the devel- 
opment of DASH in renal transplant recipients 
correlated with an improved overall graft outcome, 
as evidenced by fewer late rejection episodes and a 
decreased incidence of chronic rejection. 32 In this 
study the development of DASH is associated with a 
better long-term outcome. Chronic lung dysfunction 
did not develop in any of our patients who had 
positive results from the DASH test; by contrast, 
chronic lung dysfunction developed in all patients 
whose DASH test results were negative. Thus 
DASH appears to be a useful test to predict a 
subpopulation of lung allograft recipients in whom 
OB is less likely to develop. However, further stud- 
ies of the DASH test involving a larger population 
of lung allograft recipients is needed for confirma- 
tion of these findings. If confirmed, the DASH- 
positive subgroup could also be considered for a 
reduction in the immunosuppressive th rapy admin- 
istered. The corollary could also be considered, that 
is, prophylactic augmentation of immunosuppres- 
sion for patients whose DASH test results are 
negative. 
In conclusion, this study indicates that patients 
who have CMV pneumonitis or who have more 
episodes of late acute rejection appear to be at high 
risk for chronic lung dysfunction after lung trans- 
plantation. Negative DASH test results and HLA 
mismatching were also identified as risk factors. Our 
findings suggest the following approaches to patient 
management. First, prophylactic therapy for CMV 
could reduce the prevalence of chronic lung dys- 
function by reducing the frequency of CMV pneu- 
monitis. Second, increased focus on DASH may 
allow modification of immunosuppression the 
basis of the DASH test response. Regular surveil- 
lance biopsies in these patients, combined with a 
high index of suspicion, may facilitate an early 
diagnosis of chronic allograft dysfunction. However, 
it remains to be seen whether an early diagnosis of 
chronic lung dysfunction with subsequent therapy 
will improve the outcome of these patients. 
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